Search the Newsreel

The 5 Most Interesting Analyst Questions From ResMed’s Q2 Earnings Call

ResMed (RMD) reported steady revenue growth but a decline in operating margin for its Q2 earnings, largely due to higher R&D and supply chain costs, and a $42 million charge for a field safety action. Analysts focused on gross margin drivers, revenue growth acceleration, …

ResMed Inc. stock falls Friday, underperforms market

ResMed Inc. (RMD) stock decreased by 1.01% to $224.46 on Friday, underperforming the broader market as the S&P 500 and Dow Jones Industrial Average also experienced declines. This fall ended a four-day winning streak for the company's shares.

ResMed (RMD) Q4 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Investor Relations Officer-Salli Schwartz Chairman and Chief Executive Officer-Mick Farrell Chief Financial Officer-Aaron Bloomer Full Conference Call Transcript Operator: Hello, and welcome to the Q4 Fiscal Year …

How Investors May Respond To ResMed (RMD) Dividend Hike And Ventilator Recall Headwinds

ResMed Inc. recently announced increased fourth-quarter and full-year sales, a quarterly dividend hike to US$0.66 per share, and the completion of a US$1.40 billion share buyback program. However, these positive developments are overshadowed by a softer outlook due to an FDA Class 1 recall …

RESMED INC. : RBC RAISES TARGET PRICE TO $244 FROM $234

RBC has increased its target price for ResMed Inc. (RMD) to $244 from $234. This adjustment suggests an updated analyst outlook on the company's stock performance. The news was reported by Reuters on August 7th.

ResMed Inc. Files Annual Form 10-K Report for Fiscal Year Ended June 30, 2026

ResMed Inc. has filed its annual Form 10-K report with the U.S. SEC for the fiscal year ended June 30, 2026, detailing key corporate and financial information. The report confirmed that as of August 10, 2026, ResMed had 144,252,306 shares of Common Stock outstanding …

RESMED INC FY 2026: Revenue $5.65B, EPS $10.43— 10-K Summary

ResMed Inc. reported strong fiscal year 2026 results, with net revenue climbing to $5.65 billion, a 9.9% increase year-over-year, and diluted EPS reaching $10.43. The company saw growth across all regions, driven by device and mask sales, and improved operational efficiencies led to a …

Handelsbanken Fonder AB Raises Stock Position in ResMed Inc. $RMD

Weekly Earnings Wrap: CBA, REA Group, Westpac, Resmed and more

This article provides a weekly wrap-up of earnings season, focusing on major Australian companies like CBA, REA Group, Westpac, ResMed, and Life360. It highlights varying performances, with REA Group benefiting from property market changes and ResMed showing resilient growth despite missed guidance. The report …

ResMed Inc. Stock 12‑Month Price Target Cut to $258.47, Implies 14% Upside

The average 12-month price target for ResMed Inc. (RMD) stock has been revised down slightly to $258.47 from $261.36, as estimated by 22 analysts. This new target suggests a potential 14% upside from the Aug. 12 closing price. The consensus rating among 29 analysts …

ResMed (RMD) Stock May Be 31% Undervalued After Soft FY27 Outlook

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. ResMed stock has lagged over the past year, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and the market multiples currently point to the shares …

Is Recall-Hit Outlook and Bigger Payout Altering The Investment Case For ResMed (RMD)?

In early August 2026, ResMed reported past fourth-quarter and full-year results showing higher sales and earnings, announced a 10% increase in its quarterly US$0.66 dividend, and confirmed completion of a long-running US$1.40 billions share buyback program. At the same time, management issued a softer …

ResMed CEO Michael Farrell sells $1.03m in company stock

Michael J. Farrell, CEO of ResMed Inc. (NYSE:RMD), sold 4,991 shares of company stock worth approximately $1.03 million on August 7, 2026, while also acquiring 4,991 shares through option exercise for $730,382. These transactions were executed under a Rule 10b5-1 trading plan. ResMed recently …

Insider Selling: ResMed (NYSE:RMD) CEO Sells $1,026,598.79 in Stock

ResMed CEO Michael Farrell sold 4,991 shares of company stock worth approximately $1.03 million under a pre-arranged trading plan, reducing his stake by 1.06%. Despite this insider selling, ResMed reported strong financial results, beating EPS estimates and increasing its quarterly dividend. The company also …

Assenagon Asset Management S.A. Grows Stock Holdings in ResMed Inc. $RMD

Assenagon Asset Management S.A. significantly increased its stake in ResMed Inc. by 48.2% in the second quarter, now owning 83,852 shares valued at $16.34 million. This move is part of a broader trend of institutional investors adjusting their positions in ResMed, with hedge funds …

Ord Minnett Remains a Buy on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)

Ord Minnett has maintained a Buy rating on Resmed Inc CHESS Depositary Interests (RMD) with a price target of A$36.20. This positive outlook is echoed by Morgans, while Citi recently assigned a Hold rating. Resmed reported strong financial results for the quarter ending March …

ResMed Inc. stock rises Monday, outperforms market

ResMed Inc. (RMD) stock rose 3.83% to $220.05 on Monday, outperforming a generally down market where the S&P 500 Index fell 0.06% and the Dow Jones Industrial Average dropped 0.11%. This gain ended a two-day losing streak for the company's shares.

Operating margin % of ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh – HAM:RMEA

This article provides the operating margin percentage for ResMed Inc. CHESS Depositary Interests (HAM:RMEA) on the Hamburg Stock Exchange. The information presented is for a specific period and includes the value, change, and percentage change of the operating margin. The data is sourced from …

Resmed Inc Stock (RMD) Moved Up by 3.01% on Aug 10: Key Drivers Unveiled

Resmed Inc (RMD) stock rose by 3.01% on August 10th, driven by strong recurring revenue from its AirSense platform, positive clinical insights linking GLP-1 drugs to increased sleep apnea diagnoses, and solidified market share due to a competitor's regulatory issues. The company's performance is …

Resmed’s stock falls by 7% on soft FY27 outlook

Resmed's shares fell by around 7% after the company forecast a softer than expected fiscal year 2027 (FY27) outlook due to suspended ventilator sales, ongoing macro uncertainty and inflation across electronic components and freight. Releasing its FY26 and Q4 FY26 results concurrently, the California-based …

ResMed Inc Balances Astral Hit With Robust Core Growth

ResMed Inc. reported robust Q4 earnings with 9% revenue growth and 16% non-GAAP EPS increase, driven by strong performance in its core sleep-therapy business and expanding margins. Despite a significant setback from a $42 million provision and sales suspension due to a field-safety action …

ResMed Q4 Earnings Call Highlights

ResMed (NYSE:RMD) Releases Earnings Results, Beats Estimates By $0.06 EPS

ResMed Inc. (RMD) Stock Forecasts

Argus has raised its target price for ResMed Inc. (RMD) to $245.00, according to a report published on August 5, 2026. ResMed is identified as a major global respiratory care device company, specializing in products for sleep apnea treatment. The company's current stock price …

Resmed Inc (RMD) Aktienanalyse & Prognose

ResMed (RMD) Stock Drops As Margin Strength Meets Higher Expectations

ResMed Price Target Raised to $244.00/Share From $234.00 by RBC Capital

RBC Capital has increased its price target for ResMed (RMD) shares to $244.00, up from the previous target of $234.00. This adjustment maintains an "Outperform" rating on the stock. The new price target suggests a potential upside from its last closing price of $219.00.

ResMed’s Q4 Earnings Beat Street Estimates, But FY27 Guidance Hides the Real Growth Rate.

Resmed Inc Stock (RMD) Closed Down by 5.22% on Aug 7: What Investors Need To Know

Resmed Inc (RMD) saw its stock close down by 5.22% on August 7th due to factors including gross margin contraction, concerns over GLP-1 weight-loss drugs impacting the CPAP market, and increased competition. The company's latest quarterly earnings revealed margin pressure from shifting product mix …

AustralianSuper Pty Ltd reveals 5.71% holding in ResMed Inc (NYSE: RMD)

AustralianSuper Pty Ltd has disclosed a significant passive ownership stake of 5.71% in ResMed Inc. This holding amounts to 8,276,381 ordinary shares, over which AustralianSuper Pty Ltd maintains sole voting and dispositive power. The disclosure was made via a Schedule 13G filing, indicating an …

ResMed Inc. (NYSE:RMD) Plans Quarterly Dividend of $0.66

ResMed Inc. (NYSE:RMD) has declared a quarterly dividend of $0.66 per share, a 10% increase from its previous dividend, payable on September 24 to shareholders of record on August 20. The medical equipment provider's annualized dividend yields approximately 1.3% and is supported by a …

Resmed Inc (RMD) Earnings Forecast: Future EPS & Revenue Growth Estimates

ResMed shares tumble as weak 2027 sales forecast eclipses quarterly profit beat

ResMed shares fell by about 6% after the company projected fiscal 2027 revenue below Wall Street expectations, largely due to the suspension of its Astral ventilator sales following an FDA recall. The company's revised guidance assumes no Astral ventilator sales in fiscal 2027, impacting …